THE TGA has published two new quality Standards, one for MDMA and another for Psilocybine products.
The Standards each specify the minimum quality requirements for both the active pharmaceutical ingredient and finished product.
The quality Standards have been registered as Therapeutic Goods Orders (TGO) on the Federal Register of Legislation.
The TGA stated that from 06 Jan next year, all MDMA and Psilocybine API and finished products supplied or manufactured in Australia must comply with the relevant TGO.
To learn more about the Standard for MDMA, CLICK HERE, and for Psilocybine, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 24
